Texas Permanent School Fund Corp Purchases 9,801 Shares of Lantheus Holdings, Inc. $LNTH

Texas Permanent School Fund Corp raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 12.5% in the 2nd quarter, Holdings Channel.com reports. The fund owned 88,298 shares of the medical equipment provider’s stock after acquiring an additional 9,801 shares during the quarter. Texas Permanent School Fund Corp’s holdings in Lantheus were worth $7,228,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Elevation Point Wealth Partners LLC acquired a new position in shares of Lantheus during the second quarter worth $26,000. Osterweis Capital Management Inc. acquired a new stake in shares of Lantheus in the 2nd quarter worth $36,000. Quarry LP grew its stake in Lantheus by 2,350.0% during the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 470 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Lantheus by 190.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after buying an additional 698 shares in the last quarter. Finally, EMC Capital Management acquired a new position in Lantheus during the 2nd quarter valued at about $93,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Trading Down 2.1%

Lantheus stock opened at $65.17 on Wednesday. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The company has a market capitalization of $4.32 billion, a price-to-earnings ratio of 27.38 and a beta of -0.10. The stock has a 50-day moving average price of $57.11 and a 200 day moving average price of $62.88.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The company had revenue of $92.51 million for the quarter. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Upgrades and Downgrades

LNTH has been the subject of several recent analyst reports. Truist Financial set a $80.00 price target on Lantheus and gave the stock a “buy” rating in a report on Thursday, December 11th. The Goldman Sachs Group set a $77.00 price objective on shares of Lantheus and gave the company a “neutral” rating in a research report on Wednesday, October 8th. Weiss Ratings cut shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. B. Riley dropped their target price on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research report on Tuesday, September 16th. Finally, TD Cowen decreased their price target on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, September 15th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and an average target price of $77.33.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.